FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 186 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Ibrutinib ESMO Highlights the Importance of Prioritising the Fight Against Cancer in Its Response to the Public Consultation on the EU4Health 2026 Work Programme ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology Workforce MOST POPULAR First-Line Pembrolizumab Continues to Show Durable Clinical Benefit After 5 Years... October 31, 2022 Starving cancer into submission January 30, 2023 Commemorating and Making History: The National Cancer Act 50th Anniversary February 8, 2021 Father Dances With Joy After Learning His Son Is Cancer Free November 14, 2021 Load more HOT NEWS FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma Καρκίνος Δέρματος How could proposed changes to data protection laws affect research? FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of...
